

IN THE CLAIMS:

In accordance with 37 C.F.R. § 1.121, please substitute for claims 1, 14, 15, and 32 the following rewritten version of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

- B¹
1. (Amended) A glucagon-like peptide-2 (GLP-2) formulation comprising:
- (a) a medically useful amount of a naturally occurring GLP-2 peptide or an analog thereof;
 - (b) a phosphate buffer in an amount sufficient to adjust the pH of the formulation to a physiologically tolerable level;
 - (c) L-histidine; and
 - (d) a bulking agent selected from the group consisting of mannitol and sucrose.

14. (Amended) The GLP-2 formulation of claim 13, wherein the GLP-2 peptide has the sequence of a GLP-2 species from an animal selected from the group consisting of a primate, rat, mouse, porcine species, oxine species, bovine species, degu, hamster, guinea pig, fish, chicken, and human.

B²

15. (Amended) The GLP-2 formulation of claim 14, wherein the GLP-2 peptide is h(Gly2)GLP-2.

B³

32. The GLP-2 formulation of claim 31, wherein the GLP-2 is h(Gly2)GLP-2.

Please add the following new claim.

- B⁴
55. (NEW) A GLP-2 formulation comprising:
- (a) a medically useful amount of a naturally occurring GLP-2 peptide or an analog thereof;
 - (b) a phosphate buffer in an amount sufficient to adjust the pH of the formulation to a physiologically tolerable level;
 - (c) L-histidine in an amount sufficient to stabilize the formulation; and
 - (d) a bulking agent selected from the group consisting of mannitol and sucrose.